首页> 外文期刊>Stem Cell Research & Therapy >Human limbal fibroblast-like stem cells induce immune-tolerance in autoreactive T lymphocytes from female patients with Hashimoto’s thyroiditis
【24h】

Human limbal fibroblast-like stem cells induce immune-tolerance in autoreactive T lymphocytes from female patients with Hashimoto’s thyroiditis

机译:人角膜缘成纤维细胞样干细胞诱导桥本甲状腺炎女性患者自身反应性T淋巴细胞的免疫耐受

获取原文
           

摘要

Background Due to their “natural immune privilege” and immunoregulatory properties human fibroblast-like limbal stem cells (f-LSCs) have acquired great interest as a potential tool for achieving immunotolerance. Hashimoto’s thyroiditis (HT) is the most common thyroid autoimmune disease and cause of hypothyroidism. To date, conventional hormone replacement therapy and unspecific immunosuppressive regimens cannot provide a definitive cure for HT subjects. We explored the immunosuppressant potential of human f-LSCs on circulating lymphomonocytes (PBMCs) collected from healthy donors and female HT patients. Methods We assessed the immunophenotyping of f-LSCs, both untreated and after 48?h of proinflammatory cytokine exposure, by means of quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and flow cytometry. The immunosuppressant effects of f-LSCs on healthy activated PBMCs were investigated in cell-cell contact and transwell settings through cell cycle assay, acridine orange staining, and caspase-3 detection. We also studied T-cell responses and possible Treg conversion by means of flow cytometry. Functional assays were conducted in activated HT lymphocytes cocultured with f-LSCs after carboxyfluorescein succinimidyl ester labeling and intracellular detection of pro- and anti-inflammatory cytokines. Results The hypo-immunogenicity of the f-LSC population depended on both cell contact and soluble factors produced, as well as the undetectable expression of all those molecules required to fully activate T lymphocytes. Following exposure to Th1 cytokines, f-LSCs augmented expression of programmed death-ligand 1 and 2 (PDL-1 and -2), indoleamine-pyrrole-2,3-dioxygenase (IDO), interleukin (IL)-6, and monocyte chemotactic protein 1 (MCP-1) while maintaining their negative phenotype for major histocompatibility (MHC) class II and costimulatory molecules. During coculture, f-LSCs suppressed up to 40% of proliferation in healthy activated PBMCs, arrested them in the G0/G1 cell cycle phase without inducing apoptosis cascade, inverted the CD4/CD8 ratio, and promoted sustained expression of the immunomodulator marker CD69. Under coculture conditions the Th imbalance of autoreactive T cells from female HT patients was fully restored. Conclusions Our study describes an in vitro coculture system able to prevent inappropriate activation of autoreactive T lymphocytes of female HT patients and to generate a tolerogenic environment even in an inflammatory background. Further investigations are necessary to establish whether this stem cell-based therapy approach in HT could avoid lifetime hormone replacement therapy by inducing T-cell education.
机译:背景技术由于人类成纤维样角膜缘干细胞(f-LSCs)具有“天然免疫特权”和免疫调节特性,因此作为获得免疫耐受的潜在工具引起了人们的极大兴趣。桥本甲状腺炎(HT)是最常见的甲状腺自身免疫性疾病,是甲状腺功能减退的原因。迄今为止,常规激素替代疗法和非特异性免疫抑制方案尚不能为HT受试者提供明确的治疗方法。我们探讨了人类f-LSC对从健康供体和女性HT患者收集的循环淋巴细胞(PBMC)的免疫抑制潜力。方法我们通过定量逆转录聚合酶链反应(qRT-PCR)和流式细胞术评估了未治疗的f-LSCs和促炎性细胞因子暴露后48h后的免疫表型。通过细胞周期测定,a啶橙染色和caspase-3检测,在细胞与细胞接触和穿透的条件下研究了f-LSC对健康活化的PBMC的免疫抑制作用。我们还通过流式细胞术研究了T细胞反应和可能的Treg转化。在羧基荧光素琥珀酰亚胺酯标记并在细胞内检测促炎和抗炎细胞因子后,在与f-LSCs共培养的活化HT淋巴细胞中进行功能测定。结果f-LSC群体的低免疫原性取决于细胞接触和产生的可溶性因子,以及完全激活T淋巴细胞所需的所有那些分子的不可检测表达。暴露于Th1细胞因子后,f-LSC增强了程序性死亡配体1和2(PDL-1和-2),吲哚胺-吡咯-2,3-双加氧酶(IDO),白介素(IL)-6和单核细胞的表达趋化蛋白1(MCP-1),同时保持其对主要组织相容性(MHC)II类和共刺激分子的阴性表型。在共培养过程中,f-LSCs抑制了健康激活的PBMC中高达40%的增殖,将其阻滞在G0 / G1细胞周期阶段而没有诱导细胞凋亡级联反应,反转了CD4 / CD8比率,并促进了免疫调节标记CD69的持续表达。在共培养条件下,女性HT患者自身反应性T细胞的Th失衡得以完全恢复。结论我们的研究描述了一种体外共培养系统,该系统能够防止女性HT患者自身反应性T淋巴细胞的异常激活,即使在炎性背景下也能产生致耐受的环境。有必要进行进一步的研究来确定这种基于干细胞的HT治疗方法是否可以通过诱导T细胞教育来避免终生激素替代治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号